Gastroenterology News

Glecirasib exhibited antitumor activity among patients with pancreatic ductal adenocarcinoma and other solid tumors harboring the KRAS G12C mutation variant, study findings presented at ASCO Gastrointestinal Cancers Symposium showed.

Inflammatory bowel disease phenotype and behavior vary by race and immigration status, with foreign-born patients of all races experiencing less severe disease and later onset than those born in the U.S., researchers reported.

The CDC expanded its warning on eating charcuterie meats after the number of cases in a multistate Salmonella outbreak doubled over the last 2 weeks.

California hospitals detected a high incidence of Clostridioides difficile infection among outpatients treated for diarrhea despite a low rate of testing, suggesting that outpatient C. difficile may be underdiagnosed, researchers said.

In the latest installment of Healio’s diversity, equity and inclusion video series with the ASGE, Catherine T. Hudson, MD, addressed how to combat emerging stigma around new anti-obesity medications such as glucagon-like peptide agonists.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.